How Mankind Pharma’s Bharat Serums Acquisition Could Impact Revenues
Mankind Pharma Ltd. has announced a landmark deal to acquire a 100% stake in Bharat Serums and Vaccines Ltd. for an enterprise value of Rs 13,630 crore. This strategic acquisition could help the company expand its footprint in the specialty pharma sector. It also brings a whopping Rs 17,000-crore revenue potential for Mankind, if the transaction is completed by next year.
The acquisition's valuation reveals an enterprise value/sales multiple of 7.9 times for FY24 and 6.6 times for FY25. On an EV/EBITDA basis, the acquisition multiple is 22-24 times for FY25. The deal will be financed through internal accruals, a mix of debt and equity. Shareholders of the company have approved an equity raise of up to Rs 7,500 crore via qualified institutional placement.
Mankind has increased its debt raise limit by Rs 2,000 crore to Rs 12,500 crore. Currently, the company's long-term borrowings stand at Rs 1,711 crore, with cash reserves of Rs 1,230 crore.
Financial Impact
Mankind anticipates that this acquisition will drive double-digit growth in both topline and Ebitda, according to a press statement. The acquisition is expected to be EPS accretive from the second full year onwards, with synergy benefits further accelerating EPS accretion. It is expected to close within the next three-four months, it said.
About Bharat Serums And Vaccines
BSV is a leading branded specialty pharma platform with a strong focus on women's health. The company has presence in 12 out of the top 15 infertility drugs, and its top 10 brands accounted for 60% of domestic revenue in FY24. BSV operates within a high entry barrier portfolio, ensuring a competitive edge and sustained profitability.
The company boasted an Ebitda margin of 23% in FY24, while adjusted Ebitda margin stood at 28%. Sales CAGR was at 21% from FY21-24. BSV's net debt/EBITDA ratio is projected to be less than 2 times by FY26. The company's revenue distribution includes 54% from India, with the remaining from branded international markets.
Financial Projections Post Acquisition
Following the acquisition, Mankind's revenue could stand at Rs 17,000 crore in FY26 based on a compunded annal growth rate of 18-20%, as per NDTV Profit calculations. While, its Ebitda could reach Rs 4,258 crore.
In FY24, Mankind Pharma reported an interest expense of Rs 33.5 crore and a profit of Rs 1,941.7 crore. To finance the BSV acquisition, the company will use its internal accruals of Rs 2,000 crore from FY24-25's cash flow from operations. However, this leaves Rs 11,630 crore still needed to complete the deal.
Mankind has already received shareholder approval to raise Rs 7,500 crore through equity. It will seek bridge financing initially to complete the transaction and thereafter it will replace the debt by equity it will raise. At the end of the transaction, post equity raise, Mankind could be sitting on a gross debt level of around Rs 6,000 crore.
Financial Breakdown
Deal value: Rs 13,630 crore.
Internal accruals: Rs 2,000 crore.
Amount to raise: Rs 11,630 crore.
Approved equity raise: Rs 7,500 crore.
Working capital requirement: Rs 2,000 crore.
Existing net debt: Rs 500 crore.
Gross debt post acquisition: Rs 6,000 crore.
With an estimated interest rate of 10%, Mankind will incur an additional Rs 600 crore in interest costs for FY26.
Here is a look at what Mankind's financials could stand as after the acquisition, if it is completed by next year.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.